Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial
作者： Nicholas J. Robert , Mansoor N. Saleh , Devchand Paul , Daniele Generali , Laurent Gressot
DOI: 10.1016/J.CLBC.2011.03.005
关键词:
摘要: Introduction A multicenter, open-label phase III study was conducted to test whether sunitinib plus paclitaxel prolongs progression-free survival (PFS) compared with bevacizumab as first-line treatment for patients HER2− advanced breast cancer.
core.ac.uk
units.it
elsevier.com参考文章(28)
A D Seidman, A Tiersten, C Hudis, M Gollub, S Barrett, T J Yao, J Lepore, T Gilewski, V Currie, J Crown, Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. Journal of Clinical Oncology. ,vol. 13, pp. 2575- 2581 ,(1995) , 10.1200/JCO.1995.13.10.2575
Janna Paulsson, Tobias Sjöblom, Patrick Micke, Fredrik Pontén, Göran Landberg, Carl-Henrik Heldin, Jonas Bergh, Donal J. Brennan, Karin Jirström, Arne Östman, Prognostic Significance of Stromal Platelet-Derived Growth Factor β-Receptor Expression in Human Breast Cancer The American Journal of Pathology. ,vol. 175, pp. 334- 341 ,(2009) , 10.2353/AJPATH.2009.081030
Lesley J. Murray, Tinya J. Abrams, Kelly R. Long, Theresa J. Ngai, Lisa M. Olson, Weiru Hong, Paul K. Keast, Jacqueline A. Brassard, Anne Marie O'Farrell, Julie M. Cherrington, Nancy K. Pryer, SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clinical & Experimental Metastasis. ,vol. 20, pp. 757- 766 ,(2003) , 10.1023/B:CLIN.0000006873.65590.68
S. George, J.Y. Blay, P.G. Casali, A. Le Cesne, P. Stephenson, S.E. DePrimo, C.S. Harmon, C.N.J. Law, J.A. Morgan, I. Ray-Coquard, V. Tassell, D.P. Cohen, G.D. Demetri, Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. European Journal of Cancer. ,vol. 45, pp. 1959- 1968 ,(2009) , 10.1016/J.EJCA.2009.02.011
L Berlin, Standard of care. American Journal of Roentgenology. ,vol. 170, pp. 275- 278 ,(1998) , 10.2214/AJR.170.2.9456928
J. Baselga, H. Roché, F. Costa, J. Getúlio Martins Segalla, H. Pinczowski, E. Ma Ciruelos, S. Cabral Filho, P. Gómez, B. Van Eyll, , SOLTI-0701: A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer (BC). General Session Abstracts. ,vol. 69, pp. 45- 45 ,(2009) , 10.1158/0008-5472.SABCS-09-45
Dong Wook Kim, Young Suk Jo, Hye Sook Jung, Hyo Kyun Chung, Jung Hun Song, Ki Cheol Park, Su Hyeon Park, Jung Hwan Hwang, So Young Rha, Gi Ryang Kweon, Su-Jae Lee, Ki-Won Jo, Minho Shong, An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. The Journal of Clinical Endocrinology and Metabolism. ,vol. 91, pp. 4070- 4076 ,(2006) , 10.1210/JC.2005-2845
Carlos H Barrios, David Hernandez‐Barajas, Michael P Brown, Se‐Hoon Lee, Luis Fein, Jin‐Hwang Liu, Subramanian Hariharan, Bridget A Martell, Jinyu Yuan, Akintunde Bello, Zhixiao Wang, Rajiv Mundayat, Sun‐Young Rha, None, Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Cancer. ,vol. 118, pp. 1252- 1259 ,(2012) , 10.1002/CNCR.26440
Olga Potapova, A. Douglas Laird, Michelle A. Nannini, Angela Barone, Guangmin Li, Katherine G. Moss, Julie M. Cherrington, Dirk B. Mendel, Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Molecular Cancer Therapeutics. ,vol. 5, pp. 1280- 1289 ,(2006) , 10.1158/1535-7163.MCT-03-0156
W. Gradishar, V. Kaklamani, T. Prasad Sahoo, D. Lokanatha, V. Raina, S. Bondarde, M. Jain, A Double-Blind, Randomized, Placebo-Controlled, Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib (SOR) in Combination with Paclitaxel (PAC) as a First-Line Therapy in Patients (pts) with Locally Recurrent or Metastatic Breast Cancer (BC). General Session Abstracts. ,vol. 69, pp. 44- 44 ,(2009) , 10.1158/0008-5472.SABCS-09-44